Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1)

A method of reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or HIV-1 propagation in a subject, comprising administering to said subject a therapeutically effective amount of a compound of Formula IB, or a pharmaceutically acceptable salt thereof:

• wherein
• Cy is aryl optionally substituted with a C1-C6 alkyl substituent, or heteroaryl;
• X is NH or CH;
• Y is C(O), or O—N═N;
• and
• n is 0 or 1;
• when n is 0 then A and B are both carbons fused to a phenyl group to create a 8-membered bicyclic ring;
• or
• when n is 1 then A and B are each independently CH;
• or B is CH, CCH3 or CCH2CH3.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula IB, or a pharmaceutically acceptable salt thereof:

• wherein
• Cy is aryl optionally substituted with a C1-C6 alkyl substituent, or heteroaryl;
• X is NH or CH;
• Y is C(O), or O—N═N;
• and
• n is 0 or 1;
• when n is 0 then A and B are both carbons fused to a phenyl group to create a 8-membered bicyclic ring;
• or
• when n is 1 then A and B are each independently CH;
• or B is CH, CCH3 or CCH2CH3 and wherein said composition is formulated for reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or HIV-1 propagation in a subject.